Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

YOSAFE TEMESGEN WAKWAYA

Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease

NPI
1205275336
CMS profile
426088
Location
DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$1,564.25

70 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,564.25 70

By paying entity

PY2025 · entire year · sorted by reported total

Page 1 of 2; records 1–50 of 70 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

YOSAFE TEMESGEN WAKWAYA

NPI 1205275336 · CMS profile ID 426088

Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease

DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 2; records 1–50 of 70 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1205275336?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
YOSAFE TEMESGEN WAKWAYA, NPI 1205275336, CMS profile ID 426088. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 70 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1205275336?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). YOSAFE TEMESGEN WAKWAYA, NPI 1205275336, CMS profile ID 426088. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 70 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1205275336?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
YOSAFE TEMESGEN WAKWAYA, NPI 1205275336, CMS profile ID 426088, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 2; records 1–50 of 70 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1205275336?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

70 matching records · $1,564.25 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 70 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 70.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $30.1512/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228334702 CMS
GlaxoSmithKline, LLC. $21.7812/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190399346 CMS
GENZYME CORPORATION $34.8012/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233653081 CMS
Merck Sharp & Dohme LLC $31.0412/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238055947 CMS
Amgen Inc. $27.9611/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228334704 CMS
Grifols USA, LLC $22.7211/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249571887 CMS
Regeneron Healthcare Solutions, Inc. $25.4911/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1213066244 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $20.4411/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222978533 CMS
GlaxoSmithKline, LLC. $21.7811/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190360035 CMS
AstraZeneca Pharmaceuticals LP $14.3111/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206620671 CMS
AstraZeneca Pharmaceuticals LP $22.7411/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207141125 CMS
Insmed, Inc. $25.1911/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186303640 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $35.5311/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222978541 CMS
GlaxoSmithKline, LLC. $21.7110/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190815613 CMS
GlaxoSmithKline, LLC. $22.9910/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191314472 CMS
Insmed, Inc. $31.0010/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186296265 CMS
GENZYME CORPORATION $30.5810/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233653093 CMS
Insmed, Inc. $3.8209/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186280840 CMS
GlaxoSmithKline, LLC. $17.3109/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190389601 CMS
Insmed, Inc. $13.6009/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186283604 CMS
Insmed, Inc. $13.6009/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186288680 CMS
Grifols USA, LLC $28.6809/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249571885 CMS
Merck Sharp & Dohme LLC $34.6709/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238236419 CMS
Verona Pharma, Inc. $20.0109/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233763716 CMS
Amgen Inc. $15.8709/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228334706 CMS
Insmed, Inc. $24.8108/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186319328 CMS
GlaxoSmithKline, LLC. $15.9508/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191118920 CMS
AstraZeneca Pharmaceuticals LP $19.0408/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206875479 CMS
GlaxoSmithKline, LLC. $23.7708/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191459695 CMS
Insmed, Inc. $18.0607/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186290358 CMS
Vifor Pharma, Inc. $27.4407/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1172030571 CMS
GlaxoSmithKline, LLC. $21.7107/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190625994 CMS
AstraZeneca Pharmaceuticals LP $17.5606/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207285768 CMS
Insmed, Inc. $21.1906/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186269316 CMS
Electromed, Inc. $19.1606/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224597761 CMS
GlaxoSmithKline, LLC. $21.7106/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190994864 CMS
Merck Sharp & Dohme LLC $24.7306/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238284289 CMS
GlaxoSmithKline, LLC. $24.5005/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190823177 CMS
Grifols USA, LLC $27.1505/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249571883 CMS
Insmed, Inc. $25.3505/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186313203 CMS
GlaxoSmithKline, LLC. $21.7205/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191603653 CMS
AstraZeneca Pharmaceuticals LP $15.0805/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207304896 CMS
AstraZeneca Pharmaceuticals LP $17.5605/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206841797 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $25.6705/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1173614870 CMS
Verona Pharma, Inc. $23.4305/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233763746 CMS
Amgen Inc. $13.5804/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227087103 CMS
Merck Sharp & Dohme LLC $21.6504/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238236421 CMS
GlaxoSmithKline, LLC. $18.7304/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191526465 CMS
AstraZeneca Pharmaceuticals LP $20.0504/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207189659 CMS
GlaxoSmithKline, LLC. $21.7204/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191755251 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2021 $107.72 5
PY2022 $116.96 6
PY2023 $11,034.61 30
PY2024 $1,196.51 53
PY2025 $1,564.25 70

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $164,888.09 66
PY2024 Principal investigator $189,324.86 55
PY2023 Principal investigator $66,320.20 20
PY2022 Principal investigator $4,000.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

55 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 United Therapeutics Corporation $260.00 12/24/2024 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622576
Principal investigator 1 United Therapeutics Corporation $336.75 12/24/2024 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622578
Principal investigator 1 United Therapeutics Corporation $1,122.51 12/24/2024 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622582
Principal investigator 1 United Therapeutics Corporation $1,913.60 12/24/2024 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622586
Principal investigator 1 United Therapeutics Corporation $2,496.00 12/24/2024 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622592
Principal investigator 1 United Therapeutics Corporation $6,496.10 12/24/2024 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622600
Principal investigator 1 United Therapeutics Corporation $2,496.00 12/24/2024 Non-covered Recipient Entity
Baylor Research Institute
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622614
Principal investigator 1 United Therapeutics Corporation $2,300.00 12/06/2024 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1149622560
Principal investigator 1 United Therapeutics Corporation $1,000.00 11/26/2024 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622580
Principal investigator 1 United Therapeutics Corporation $1,830.40 11/26/2024 Non-covered Recipient Entity
Baylor Research Institute
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622602
Principal investigator 1 United Therapeutics Corporation $2,300.00 11/13/2024 Non-covered Recipient Entity
Baylor Research Institute
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622610
Principal investigator 1 United Therapeutics Corporation $130.00 10/30/2024 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622574
Principal investigator 1 United Therapeutics Corporation $2,080.00 10/30/2024 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622590
Principal investigator 1 United Therapeutics Corporation $5,718.70 10/30/2024 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622598
Principal investigator 1 United Therapeutics Corporation $2,080.00 10/30/2024 Non-covered Recipient Entity
Baylor Research Institute
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622606
Principal investigator 1 United Therapeutics Corporation $5,436.60 10/30/2024 Non-covered Recipient Entity
Baylor Research Institute
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622622
Principal investigator 1 United Therapeutics Corporation $1,750.00 10/09/2024 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1149622554
Principal investigator 1 United Therapeutics Corporation $1,750.00 10/09/2024 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1149622556
Principal investigator 1 United Therapeutics Corporation $1,950.00 10/09/2024 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1149622558
Principal investigator 1 United Therapeutics Corporation $2,958.00 10/09/2024 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1149622562
Principal investigator 1 United Therapeutics Corporation $8,600.00 10/09/2024 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1149622564
Principal investigator 1 United Therapeutics Corporation $16,900.00 10/09/2024 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1149622566
Principal investigator 1 United Therapeutics Corporation $130.00 10/09/2024 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622572
Principal investigator 1 United Therapeutics Corporation $1,996.80 10/09/2024 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622588
Principal investigator 1 United Therapeutics Corporation $4,900.00 10/09/2024 Non-covered Recipient Entity
Baylor Research Institute
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622620
Principal investigator 1 United Therapeutics Corporation $1,260.00 09/25/2024 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622584
Principal investigator 1 United Therapeutics Corporation $5,135.00 09/25/2024 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622596
Principal investigator 1 United Therapeutics Corporation $1,996.80 09/25/2024 Non-covered Recipient Entity
Baylor Research Institute
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622604
Principal investigator 1 United Therapeutics Corporation $2,300.00 09/18/2024 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1149622568
Principal investigator 1 United Therapeutics Corporation $2,329.60 08/28/2024 Non-covered Recipient Entity
Baylor Research Institute
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622612
Principal investigator 1 United Therapeutics Corporation $3,919.50 08/28/2024 Non-covered Recipient Entity
Baylor Research Institute
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622618
Principal investigator 1 United Therapeutics Corporation $2,828.80 08/08/2024 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622594
Principal investigator 1 United Therapeutics Corporation $2,300.00 08/08/2024 Non-covered Recipient Entity
Baylor Research Institute
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622608
Principal investigator 1 United Therapeutics Corporation $2,828.80 07/31/2024 Non-covered Recipient Entity
Baylor Research Institute
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622616
Principal investigator 1 United Therapeutics Corporation $130.00 07/10/2024 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622570
Principal investigator 1 United Therapeutics Corporation $1,000.00 06/26/2024 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622630
Principal investigator 1 United Therapeutics Corporation $2,246.40 06/26/2024 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622638
Principal investigator 1 United Therapeutics Corporation $2,300.00 06/26/2024 Non-covered Recipient Entity
Baylor Research Institute
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622644
Principal investigator 1 United Therapeutics Corporation $10,574.00 06/26/2024 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622658
Principal investigator 1 United Therapeutics Corporation $14,643.20 06/26/2024 Non-covered Recipient Entity
Baylor Research Institute
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622662
Principal investigator 1 United Therapeutics Corporation $2,300.00 06/12/2024 Non-covered Recipient Entity
Baylor Research Institute
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622642
Principal investigator 1 United Therapeutics Corporation $130.00 05/22/2024 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622626
Principal investigator 1 United Therapeutics Corporation $2,382.90 05/22/2024 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622646
Principal investigator 1 United Therapeutics Corporation $2,382.90 05/22/2024 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622648
Principal investigator 1 United Therapeutics Corporation $260.00 05/08/2024 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622628
Principal investigator 1 United Therapeutics Corporation $2,876.00 05/08/2024 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622650
Principal investigator 1 United Therapeutics Corporation $10,341.50 04/10/2024 Non-covered Recipient Entity
Baylor Research Institute
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622656
Principal investigator 1 United Therapeutics Corporation $130.00 03/27/2024 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622624
Principal investigator 1 United Therapeutics Corporation $1,929.00 03/27/2024 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622636
Principal investigator 1 United Therapeutics Corporation $7,900.00 03/13/2024 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622654
Principal investigator 1 United Therapeutics Corporation $1,664.00 02/28/2024 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622632
Principal investigator 1 United Therapeutics Corporation $2,300.00 02/28/2024 Non-covered Recipient Entity
Baylor Research Institute
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622640
Principal investigator 1 United Therapeutics Corporation $11,466.00 02/28/2024 Non-covered Recipient Entity
Baylor Research Institute
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622660
Principal investigator 1 United Therapeutics Corporation $1,780.00 01/31/2024 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622634
Principal investigator 1 United Therapeutics Corporation $6,759.00 01/31/2024 Non-covered Recipient Entity
Baylor Research Institute
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149622652